0.4502
price down icon3.60%   -0.0168
after-market Handel nachbörslich: .45 -0.0002 -0.04%
loading
Schlusskurs vom Vortag:
$0.467
Offen:
$0.459
24-Stunden-Volumen:
612.64K
Relative Volume:
0.65
Marktkapitalisierung:
$129.27M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-0.5699
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
+3.83%
1M Leistung:
-14.28%
6M Leistung:
-51.43%
1J Leistung:
-79.54%
1-Tages-Spanne:
Value
$0.4217
$0.478
1-Wochen-Bereich:
Value
$0.4217
$0.49
52-Wochen-Spanne:
Value
$0.3931
$2.875

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Firmenname
Lyell Immunopharma Inc
Name
Telefon
650 695-0677
Name
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Mitarbeiter
300
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
LYEL's Discussions on Twitter

Vergleichen Sie LYEL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LYEL
Lyell Immunopharma Inc
0.4502 129.27M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-30 Herabstufung BofA Securities Buy → Underperform
2024-06-27 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-28 Herabstufung JP Morgan Overweight → Neutral
2022-11-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-11 Herabstufung Goldman Buy → Neutral
2022-10-17 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet BofA Securities Buy
2021-07-12 Eingeleitet Goldman Buy
2021-07-12 Eingeleitet JP Morgan Overweight
2021-07-12 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

pulisher
Apr 24, 2025

A better buy-in window may exist right now for Lyell Immunopharma Inc (LYEL) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 35,640 shares worth 19958.0. - knoxdaily.com

Apr 24, 2025
pulisher
Apr 22, 2025

Can you now get a good deal on Lyell Immunopharma Inc’s shares? - uspostnews.com

Apr 22, 2025
pulisher
Apr 19, 2025

Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Lyell Immunopharma gets FDA RMAT status for lymphoma treatment - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients - Stock Titan

Apr 15, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Cuts Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 - Investing.com

Apr 10, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 07, 2025

CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition - Fierce Pharma

Apr 07, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 By Investing.com - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Lyell Immunopharma to close West Hills facility, cut 73 jobs By Investing.com - Investing.com India

Apr 02, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener

Apr 01, 2025
pulisher
Mar 31, 2025

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025
pulisher
Mar 27, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 200,000 shares worth 0.12 million. - knoxdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Wednesday 3/26 Insider Buying Report: LYEL, LSAK - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey

Mar 25, 2025
pulisher
Mar 23, 2025

Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com

Mar 23, 2025
pulisher
Mar 20, 2025

Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Chief Financial Officer of Lyell Immunopharma Charles Newton Buys 989% More Shares - simplywall.st

Mar 20, 2025
pulisher
Mar 19, 2025

How to interpret Lyell Immunopharma Inc (LYEL)’s stock chart patterns - US Post News

Mar 19, 2025
pulisher
Mar 19, 2025

Lyell Immunopharma stock hits 52-week low at $0.51 By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Lyell Immunopharma director Richard Klausner purchases $94,942 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma director Richard Klausner purchases $94,942 in stock By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CFO Newton purchases $111,620 in common stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CEO Seely Lynn buys $106,190 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma CFO Newton purchases $111,620 in common stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma stock hits 52-week low at $0.51 - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

HC Wainwright Has Optimistic Outlook of LYEL Q1 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright - Defense World

Mar 15, 2025
pulisher
Mar 13, 2025

H.C. Wainwright maintains Neutral on Lyell Immunopharma stock By Investing.com - Investing.com Australia

Mar 13, 2025

Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):